RenovoRx, Inc. (NASDAQ:RNXT - Get Free Report) insider Ramtin Agah acquired 15,000 shares of the stock in a transaction dated Tuesday, April 15th. The shares were bought at an average cost of $0.90 per share, with a total value of $13,500.00. Following the transaction, the insider now directly owns 1,113,460 shares of the company's stock, valued at $1,002,114. This represents a 1.37 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link.
Ramtin Agah also recently made the following trade(s):
- On Friday, April 11th, Ramtin Agah bought 20,000 shares of RenovoRx stock. The stock was bought at an average cost of $0.80 per share, with a total value of $16,000.00.
- On Tuesday, April 8th, Ramtin Agah purchased 26,000 shares of RenovoRx stock. The stock was purchased at an average cost of $0.84 per share, for a total transaction of $21,840.00.
RenovoRx Stock Down 1.0 %
Shares of RNXT stock opened at $1.02 on Friday. RenovoRx, Inc. has a 12 month low of $0.75 and a 12 month high of $1.69. The company's fifty day simple moving average is $0.97 and its 200-day simple moving average is $1.13. The firm has a market cap of $37.28 million, a PE ratio of -1.79 and a beta of 1.12.
RenovoRx (NASDAQ:RNXT - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). The firm had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.17 million. On average, equities analysts predict that RenovoRx, Inc. will post -0.4 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the stock. Citadel Advisors LLC bought a new stake in shares of RenovoRx during the 4th quarter worth approximately $49,000. Renaissance Technologies LLC bought a new position in shares of RenovoRx in the fourth quarter valued at $84,000. Finally, Geode Capital Management LLC increased its holdings in RenovoRx by 61.9% during the third quarter. Geode Capital Management LLC now owns 232,937 shares of the company's stock worth $247,000 after buying an additional 89,018 shares during the last quarter. 3.10% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Separately, HC Wainwright reiterated a "buy" rating and set a $3.00 price objective on shares of RenovoRx in a report on Friday, April 4th.
Read Our Latest Stock Report on RNXT
RenovoRx Company Profile
(
Get Free Report)
RenovoRx, Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to contact@insidertrades.com.
